SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Bertrand Tombal, Michael Borre, Per Rathenborg, Patrick Werbrouck, Hendrik Van Poppel, Axel Heidenreich, Peter Iversen, Johan Braeckman, Jiri Heracek, Edwina Baskin-Bey, Taoufik Ouatas, Frank Perabo, De Phung, Benoit Baron, Mohammad Hirmand, Matthew R. Smith, Long-term Efficacy and Safety of Enzalutamide Monotherapy in Hormone-naïve Prostate Cancer: 1- and 2-Year Open-label Follow-up Results, European Urology, 2015, 68, 5, 787

    CrossRef

  2. 2
    Ajjai Alva, Maha Hussain, Optimal Pharmacotherapeutic Management of Hormone-Sensitive Metastatic Prostate Cancer, Drugs, 2013, 73, 14, 1517

    CrossRef

  3. 3
    D. Rossi, P. Beuzeboc, F. Staerman, M.-O. Timsit, A. Benchikh El Fegoun, Cancer de la prostate localement avancé et hormonothérapie, Progrès en Urologie, 2010, 20, S68

    CrossRef

  4. 4
    Paul Sinfield, Richard Baker, Janette Camosso-Stefinovic, Andrew M. Colman, Carolyn Tarrant, John K. Mellon, William Steward, Roger Kockelbergh, Shona Agarwal, Men’s and carers’ experiences of care for prostate cancer: a narrative literature review, Health Expectations, 2009, 12, 3
  5. 5
    Henry Botto, Morgan Rouprét, François Mathieu, François Richard, Etude randomisée multicentrique comparant la castration médicale par triptoréline à la castration chirurgicale dans le traitement du cancer de la prostate localement avancé ou métastatique, Progrès en Urologie, 2007, 17, 2, 235

    CrossRef

  6. 6
    Frank Kunath, Henrik R Grobe, Gerta Rücker, Edith Motschall, Gerd Antes, Philipp Dahm, Bernd Wullich, Joerg J Meerpohl, Non-steroidal antiandrogen monotherapy compared with luteinising hormone–releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer, The Cochrane Library,